Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012

Clinical Infectious Diseases

Volumn 59, Issue 11, 2014, Pages 1519-1524

  Heikkinen, Terho ^a   Ikonen, Niina ^b   Ziegler, Thedi ^b,c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Influenza B virus; Quadrivalent influenza vaccines; Trivalent influenza vaccines; Vaccine mismatch

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; AGED; CHILD; EPIDEMIC; FINLAND; GROUPS BY AGE; HUMAN; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; NONHUMAN; PANDEMIC; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; ADULT; IMMUNOLOGY; INFANT; INFECTION CONTROL; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MASS IMMUNIZATION; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DISEASE NOTIFICATION; FINLAND; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MASS VACCINATION; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84922777934     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu664     Document Type: Review

References (25)

1. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Co-circulation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175: 59-68.
2. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012; 8: 81-8.
3. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010; 28: 2149-56.
4. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011; 11: 23-9.
5. Skowronski DM, De Serres G, Dickinson J, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 2009; 199: 168-79.
6. Beran J, Wertzova V, Honegr K, et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009; 9: 2.
7. Glezen WP, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. The burden of influenza B: a structured literature review. Am J Public Health 2013; 103: e43-51.
8. Belshe RB The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28S: D45-53.
9. Paddock CD, Liu L, Denison AM, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis 2012; 205: 895-905.
10. McCullers JA, Hayden FG. Fatal influenza B infections: time to reexamine influenza research priorities. J Infect Dis 2012; 205: 870-2.
11. Bresee J, Hayden FG. Epidemic influenza: responding to the expected but unpredictable. N Engl J Med 2013; 368: 589-92.
12. Baden LR For an influenza vaccine, are two Bs better than one? N Engl J Med 2013; 369: 2547-9.
13. European Influenza Surveillance Scheme. Annual report: 2003-2004 influenza season. Utrecht, the Netherlands: NIVEL, 2005. Available at: http://www.nivel.nl/en/node/2430?database=ChoicePublicat&priref=1001232. Accessed 1 September 2014.
14. Chan PKS, Chan MCW, Cheung JLK, et al. Influenza B lineage circulation and hospitalization rates in a subtropical city, Hong Kong, 2000-2010. Clin Infect Dis 2013; 56: 677-84.
15. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-86.
16. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333-40.
17. Daley AJ, Nallusamy R, Isaacs D. Comparison of influenza A and influenza B virus infection in hospitalized children. J Paediatr Child Health 2000; 36: 332-5.
18. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis 2003; 36: 299-305.
19. Silvennoinen H, Peltola V, Lehtinen P, Vainionpää R, Heikkinen T. Clinical presentation of influenza in unselected children treated as outpatients. Pediatr Infect Dis J 2009; 28: 372-5.
20. Chi CY, Wang SM, Lin CC, et al. Clinical features of children infected with different strains of influenza B in southern Taiwan. Pediatr Infect Dis J 2008; 27: 640-5.
21. Irving SA, Patel DC, Kieke BA, et al. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses 2012; 6: 37-43.
22. Silvennoinen H, Peltola V, Vainionpää R, Ruuskanen O, Heikkinen T. Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study. Pediatr Infect Dis J 2011; 30: e24-8.
23. Silvennoinen H, Peltola V, Vainionpää R, Ruuskanen O, Heikkinen T. Admission diagnoses of children 0-16 years of age hospitalized with influenza. Eur J Clin Microbiol Infect Dis 2012; 31: 225-31.
24. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30: 1993-8.
25. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30: 7443-6.